[{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"||B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Palivizumab","moa":"Fusion glycoprotein F0","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Palivizumab","moa":"Fusion glycoprotein F0","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Biosidus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Biosidus","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Biosidus"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MB09","moa":"RANK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Mabxience","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Mabxience"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MB02","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MB02-SP","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MB04","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Pisa Farmac\u00e9utica | Laboratorios de Productos \u00c9ticos C.E.I.S.A. | Laboratorio Elea Phoenix | Tecnoquimicas S.A. | Innogene Kalbiotech | Libbs Farmaceutica | Key Oncologics | Nanolek LLC | Actoverco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"RTXM83","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Pisa Farmac\u00e9utica | Laboratorios de Productos \u00c9ticos C.E.I.S.A. | Laboratorio Elea Phoenix | Tecnoquimicas S.A. | Innogene Kalbiotech | Libbs Farmaceutica | Key Oncologics | Nanolek LLC | Actoverco","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Pisa Farmac\u00e9utica | Laboratorios de Productos \u00c9ticos C.E.I.S.A. | Laboratorio Elea Phoenix | Tecnoquimicas S.A. | Innogene Kalbiotech | Libbs Farmaceutica | Key Oncologics | Nanolek LLC | Actoverco"},{"orgOrder":0,"company":"Mabxience","sponsor":"Laboratorio Elea Phoenix | Libbs Farmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Laboratorio Elea Phoenix | Libbs Farmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Laboratorio Elea Phoenix | Libbs Farmaceutica"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Zentiva"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Abbott Laboratories"},{"orgOrder":0,"company":"Mabxience","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Mabxience","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Mabxience","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Mabxience"},{"orgOrder":0,"company":"Mabxience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Mabxience
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
